Vanedge Capital

Aegis Ventures is an next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. Our platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on three key areas: data and automation, health and wellness, and emerging sciences and technologies. "In business‌‌,‌‌ I am driven by two things - building value through knowledge and improving the world through investment‌‌.‌‌ ‌‌A‌egis V‌entures is where I translate these passions into reality‌.‌" - Aegis Chairman, Bill Schoenfeld ‌A‌egis draws on decades of experience executing $20B of global transactions since Bill Schoenfeld's founding of‌‌ A‌‌PL Group in 1994‌‌.‌‌ Differentiated Skillset & Philosophy While building businesses is equal parts art and science‌‌,‌‌ we have found that many elements of the venture creation process are identif‌iable and replicable - and can be learned by a broad array of talented individuals‌‌.‌‌ Our venture creation playbook is founded on the expertise we have formed in other asset classes and is built on the understanding that success depends upon our ability to cultivate exceptional talent across the studio‌‌.‌‌ Financial Strength & Flexibility ‌A‌ll of our capital is internal‌‌,‌‌ and we are free to invest in the time and manner we see f‌it‌‌.‌‌ With no predetermined time horizon for realizing returns‌‌,‌‌ we are empowered to pursue long‑term‌‌,‌‌ structural theses in high‑magnitude opportunities‌‌.‌‌ Freed from the burdens of fundraising‌‌,‌‌ the full breadth of our focus is devoted to the advancement of our portfolio companies and the improvement of our platform‌‌.‌‌ Incisive Risk Management ‌A‌‌egis's unif‌ied risk framework aims to identify‌‌,‌‌ track‌‌,‌‌ and execute upon distinct risk reduction milestones that maximize upside potential and minimize downside exposure‌‌.‌‌ This analytical rigor allows our entrepreneurs to develop a disciplined‌‌,‌‌ methodical approach to venture creation‌ to vet and validate ideas with greater eff‌iciency and effectiveness‌‌.‌‌

Martlet Capital has invested in more than 65 start-ups, since its launch in 2011. In 2021, Martlet successfully raised additional capital to scale its investment activity. We provide patient capital for early-stage B2B deep technology and life science start-ups, with a primary focus on companies based in Cambridge. Our team is comprised of experienced investors and entrepreneurs. In addition to capital, we can offer support, experience and a network of contacts. We have achieved several exits from our portfolio, from trade sales to global technology companies and IPO’s.

Portal Innovations is a venture capital firm that helps exceptional life sciences innovators build their companies where they live. We surround these entrepreneurs with the resources and community they need: Seed capital, fully equipped lab space, and expertise and introductions to other investors and partners. Our crafted capital™ approach provides management expertise, funding, and lab+work space to turn breakthroughs into businesses. The Problem Entrepreneurs struggle and VC firms miss investment opportunities when exceptional scientific innovators do not have the capital, lab space and management skills to grow new life sciences companies where they live. Many of these missed investments are due to the lack of relationships between universities and VCs. Our Approach For top life science innovators in emerging biotech ecosystems, we offer a clear path for them to bring their ambitions closer to reality and achieve their next round of funding. First, we provide things that are scarce: Early-stage funding, fully equipped lab space, and introductions to our trusted, global network - all built on the real-world experiences of our founders, who have taken several life sciences startups public and raised more than $750 million in venture capital. Second, investors are being drawn to these emerging markets by exceptional faculty at top-tier academic research institutions. Portal is the first mover in these emerging markets, identifying the most promising life sciences technologies and innovators through our university relationships. We then partner with our network of investors and corporations to support these startups together. Third, Portal has a number of scientists on staff to help with consulting services for our portfolio companies. Whether it’s creating a go-to-market strategy, or analyzing scientific data, we’re here to help and facilitate success in life sciences. Portal by the numbers32: number of member companies in Chicago 50,000: total square feet of lab and office space $6M: worth of world-class lab equipment 80%+ equipment needs we aim to provide to member companies From potential to performance. Our market-based approach identifies the most promising life science startups, and supports them throughout the journey. We engage deeply in every aspect of the business, leveraging our network to tackle each company’s specific challenges and lead them to successful Series A investments with world-class VCs and strategic investors. Assess We begin with a deep dive into the prospect company to examine management and strategic needs, leadership team, space requirements, and current funding. At every turn, we’re assessing opportunity and fit. Rigorous research and market understanding Seeking emerging technologies and novel approaches to big problems Build portfolio of high-potential biopharma, med tech, and data sciences ventures Invest Once selected, we begin our collaboration with company founders. We understand the many complexities of the biotech business model, and bring deep experience to help startups answer defining strategic questions, overcome roadblocks, and build capability and confidence. Support key regulatory and clinical decisions Optimize manufacturing and commercial considerations Build In the build stage, we work side-by-side with company founders to nurture and accelerate growth. We craft a robust strategic roadmap for value creation, and execute together with urgency and action. 12–18 months Vested interest in growth and value creation Best-in-class business operations, financial and strategic partnerships, and lab equipment Evolve From day one, we work with the end game in mind: prosperous execution. We guide our portfolio companies toward the most favorable next step in their journey, be it acquisition or strategic partnership. Expertise, partnership, and trust to drive successful outcomes Lasting, positive impact

We support start-ups with investments between $10M and $20M in Europe, Israel and opportunistically on the East coast of the US. Forestay is more than just a VC fund, it’s a family. Forestay was founded as the digital tech arm of a family-oriented investment group that traces its successes in business and its enduring values back across generations. The Bertarelli family founded B-FLEXION (formerly Waypoint Capital), of which Forestay is a part, in 2012 to evolve the management of the capital realised by the sale of Serono, the global leader in biotech and healthcare that they had grown over three generations of leadership. In the decade since, B-FLEXION and its businesses have generated exceptional and lasting value. B-FLEXION is an entrepreneurial private investment firm that partners with sophisticated capital to deliver exceptional value over the generations. As well as its investment funds seeding and building businesses in technology, private equity, real estate and hedge funds, B-FLEXION also focuses on growing operating businesses in transformative industries. Building on its heritage and of that of its founder and Chairman, these have been principally in life sciences, healthcare and digital health.

Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth. Taiwania Capital is a venture capital that focuses on investing in technologies and biotech areas start-ups that are Taiwan or US-based with disruptive and advanced technology. Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Investment GEO Focus: USA, EU, UK, NATO and allies. Our LPs come from NATO and allied countries. From Pre-Seed to IPO We back first time and experienced founders with the first check in Pre-seed, Seed or A round. We can follow on until IPO or a successful exit. We work with companies from their inception through their early lifecycle and can add real value - connecting them to the networks that matter most. We strive to be the founder(s)’ first call and focus on ramping up product market fit and sales. We can act as a Founding Investor if needed, transition out after reaching milestones and/or hiring professional team. “Imagination is more important that knowledge” (A. Einstein) Before we invest we validate product market fit and refine ideal customer profile. Every research paper we read (yes, we do read research papers), we see all the ways the technology can disrupt existing industries. We continue to support the startups post-investment with hands on business development, recruitment and sales when needed. Focus Areas: Resilience + Dual Use Cybersecurity DeepTech* *Biotechnology and Human Systems, Manufacturing, New Materials, Sustainability, Infrastructure, Data Analytics, Data Centers, Buildings, Logistics, Agriculture, Enterprise, AI/ML, DevOps, Data Centers, Defense.